The UK and the US have reached a pivotal agreement that keeps tariffs on UK pharmaceuticals entering the US at zero for three years. This deal is significant as it protects a major export sector worth over £5 billion annually. In return, the UK will adjust its spending on medicines through the NHS.
Earlier this year, President Trump had threatened to increase tariffs on imported drugs significantly. His administration argued that US consumers were essentially subsidizing drug costs for other countries, pushing for those nations to contribute more. Consequently, pharmaceutical exports became a sticking point in US–UK trade discussions, with the White House previously threatening to raise tariffs due to concerns about the US reliance on foreign-made medicines.
Under this new agreement, the UK will increase the price threshold for new treatments. It also aims to boost its overall spending on medicines from 0.3% to 0.6% of GDP over the next decade. The cap on the money drug companies must repay to the NHS has also been reduced, securing more financial stability for the health service.
Statistics show that in the year leading up to September, UK pharmaceutical exports to the US amounted to an impressive £11.1 billion. These exports comprised 17.4% of all UK goods sent to America.
However, the deal also underscores ongoing challenges within the UK pharmaceutical sector. Many pharmaceutical investments in the UK have stalled recently, with significant funds flowing to the US instead. For instance, GSK announced a monumental $30 billion investment in the US over the next five years, while Merck pulled back from a planned £1 billion expansion in the UK.
William Bain from the British Chambers of Commerce expressed satisfaction, stating that this new agreement could enhance the UK’s competitive edge in pharmaceutical innovation and exports. Experts highlight that maintaining zero tariffs is vital for the UK’s position in the global drug market, especially considering how crucial pharmaceuticals are to its economy.
Overall, this agreement marks a strategic win for the UK, as it solidifies its trade relationship with the US while aiming for sustainable growth in the healthcare sector.
Source link
